AOD-9604
Also known as: Fragment 177-191, hGH fragment
Growth hormone fragment that promotes fat loss through lipolysis without affecting IGF-1 or glucose.
Evidence
Emerging
FDA status
Not FDA-approved
Source
Synthetic hGH fragment (amino acids 177-191)
Overview
Growth hormone fragment that promotes fat loss through lipolysis without affecting IGF-1 or glucose.
Mechanism of Action
Binds beta-3 adrenergic receptors on adipocytes, increases cAMP/PKA signaling, activates hormone-sensitive lipase for lipolysis, inhibits lipogenic enzymes, no GH receptor binding (no IGF-1 elevation), preferentially accumulates in adipose tissue.
What research has looked at
Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.
- Promotes fat breakdown (lipolysis)
- Inhibits new fat formation (lipogenesis)
- Body fat in animal studies
- No effect on blood glucose or insulin
- Fat tissue in animal studies
- May support cartilage repair
Researched for
Research topics, not approved uses.
How Gabriel approaches peptides
Through Gabriel, licensed clinicians may prescribe BPC-157, TB-500, MOTS-c, epitalon and semax (nasal) as compounded medications from licensed 503A pharmacies, under HHS's October 28, 2026 interim policy, and only when appropriate. They are not FDA-approved, and Gabriel never gives peptide dosing. AOD-9604 isn't prescribed through Gabriel. If you're thinking about it, Gabriel can help you find a licensed clinician to look at the cause of what you're dealing with and the options with stronger evidence.
Research & Evidence
Animal studies, human trials for obesity
Animal studies reported fat loss. Human trials did not show meaningful weight loss, and development for obesity stopped.
Safety Information
Potential Side Effects
- •Injection site reactions
- •Headache (rare)
Contraindications
- Pregnancy
- Breastfeeding
Interactions
- ⚠None well-documented
Quick Facts
Related Peptides
Semaglutide
Weekly GLP-1 receptor agonist, FDA-approved as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management and other uses.
Tirzepatide
Weekly GIP and GLP-1 receptor agonist, FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for weight management and obstructive sleep apnea.
Retatrutide
Investigational weekly medicine that acts on GIP, GLP-1 and glucagon receptors. It is not FDA-approved and is not available by prescription.